Evidence map›Paper›PMID 40855272›Full record

ArticleBMC nephrology2025

Severe hypercalcemia requiring emergency hemodialysis and multidrug therapy in a case of diffuse large B-cell lymphoma with multiple bone lesions.

Yusaku Watanabe, Shohei Kaneko, Rinka Yamamoto, Toshiaki Ogishi, Sachika Okamoto, Kosuke Yuyama, Akari Matsuoka, Yuhei Nakamura, Shiori Ando, Kiyonori Ito and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yusaku WatanabeDivision of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Shohei KanekoDivision of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan. shohei.sasurai@gmail.com.
Rinka YamamotoDivision of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Toshiaki OgishiDivision of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Sachika OkamotoDivision of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Kosuke YuyamaDivision of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Akari MatsuokaDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Yuhei NakamuraDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Shiori AndoDepartment of Diagnostic Pathology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Kiyonori ItoDivision of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Keiji HiraiDivision of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Susumu OokawaraDivision of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Yoshiyuki MorishitaDivision of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSevere hypercalcemia is a rare but serious complication observed in patients with diffuse large B-cell lymphoma (DLBCL) with multiple bone lesions. Currently, no standard therapy has been established for this life-threatening condition. CASE PRESENTATION: A 54-year-old Japanese woman with severe hypercalcemia (serum total calcium concentration of 23.0 mg/dL) was referred to our hospital. Initial management included multiple sessions of emergency hemodialysis, aggressive hydration, and administration of calcitonin. Although these interventions temporarily improved her condition, her serum calcium levels soon rebounded. The addition of bisphosphonates did not induce a prompt or sufficient reduction in serum calcium levels. Computed tomography revealed osteolytic lesions, strongly suggestive of malignancy. Given that the pathological condition was attributed to bone lesions, denosumab was administered, leading to a marked reduction in serum calcium levels and sustained control. A definitive diagnosis of DLBCL was established through bone biopsy and bone marrow aspiration. Based on these findings, severe hypercalcemia was determined to be secondary to DLBCL with multiple bone lesions. Following the initiation of chemotherapy, her serum calcium levels remained stable during follow-up.

conclusionsSevere hypercalcemia in this case was caused by DLBCL with multiple bone lesions. Successful management was achieved through a combination of emergency hemodialysis, aggressive hydration, and a multi-drug regimen, including calcitonin, bisphosphonates, and denosumab.

Indexed as

Bone NeoplasmsHypercalcemiaLymphoma, Large B-Cell, DiffuseRenal DialysisAntineoplastic Combined Chemotherapy ProtocolsBone Density Conservation AgentsCalcitoninDenosumabFemaleHumansMiddle AgedBone Density Conservation AgentsCalcitoninDenosumabDenosumabDiffuse large B-cell lymphomaHemodialysisHypercalcemia

Identifiers

PMID40855272
PMCPMC12376524

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.